Agile Therapeutics, Inc. filed its 10-K on Mar 23, 2023 for the period ending Dec 31, 2022. In this report its auditor, Ernst & Young LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1.44 USD | +331.14% | +323.65% | -26.15% |
1st Jan change | Capi. | |
---|---|---|
-26.15% | 9.87M | |
+16.49% | 122B | |
+21.73% | 115B | |
+20.76% | 26.64B | |
-21.81% | 19.91B | |
-16.89% | 16.32B | |
-44.74% | 15.52B | |
-18.81% | 15.49B | |
+62.72% | 14.83B | |
+3.09% | 13.67B |
- Stock Market
- Equities
- AGRX Stock
- News Agile Therapeutics, Inc.
- Agile Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt